hek293 supertopflash  (ATCC)

Journal: Molecular Therapy. Nucleic Acids

Article Title: Use of polyadenosine tail mimetics to enhance mRNA expression from genes associated with haploinsufficiency disorders

doi: 10.1016/j.omtn.2025.102453

Figure Lengend Snippet: Poly(A) tail mimetics enhance the expression of target mRNAs (A) Schematic of the basic design of the mRNA booster: a 30-nucleotide sequence complementary to a particular region of the 3′ UTR of a targeted mRNA, which bears a poly(A) tail. (B) A poly(A) mimetic enhances the expression of an in vitro transcribed Firefly luciferase reporter in HEK293 cells, with a significant (one-way ANOVA, ∗∗∗∗ p < 0.00001) 6-fold increase in FLuc over Renilla activity when the booster bears a 200-nucleotide poly(A) tail, 48 h after transfection. The results are depicted for a booster without a poly(A) tail, with a short 10-nucleotide tail, or a long 200-nucleotide tail; for two different FLuc mRNA to booster ratios (low dose, 1:36; and high dose, 1:216). (C) Targeting an endogenous mRNA confirms the booster efficiency to enhance cellular gene expression. LSM8 mRNA levels normalized to GAPDH are represented, after treatment with 20 nM final concentration of LSM8- specific booster compared to a non-specific polyadenylated control. Cells were harvested 2, 4, 6, 8, 16, and 24 h after transfection. The comparison between control vs. booster treated in each time point indicates significant increase (∗∗) after 4-, 16- and 24-h incubation. Two-way ANOVA, ∗∗ p < 0.001, ∗∗∗∗ p < 0.00001.

Article Snippet: We tested our mRNA booster technology in HEK293 (ATCC CRL 1573), HEK293 SuperTopFlash (STF), and SH-SY5Y (ATCC CRL 2266) cell lines as well as iPSC-derived neuronal cells (see below).

Techniques: Expressing, Sequencing, In Vitro, Luciferase, Activity Assay, Transfection, Gene Expression, Concentration Assay, Control, Comparison, Incubation

Journal: Molecular Therapy. Nucleic Acids

Article Title: Use of polyadenosine tail mimetics to enhance mRNA expression from genes associated with haploinsufficiency disorders

doi: 10.1016/j.omtn.2025.102453

Figure Lengend Snippet: mRNA boosters enhance haploinsufficiency-associated mRNAs (A) Schematic of the guide sequences position on the 3′ UTR of their target genes: MECP2 , CTNNB1 , PURA , and SYNGAP1 mRNAs, used throughout the study. Guide sequences spanning distinct regions were evaluated and assigned. (B) Levels of M E CP2 mRNA measured by qRT-PCR in SH-SY5Y cells transfected with 40 nM booster V.2.2 (MB2) against 3′ UTR of the M E CP2 or a control booster not targeting M E CP2 (control) and harvested 16 h after transfection. Welch’s t test, ∗ p = 0.05. (C and D) Levels of CTNNB1 (C) and PURA (D) mRNAs measured by qRT-PCR in HEK293 cells transfected with boosters V.2.2 targeting distinct regions of the 3′ UTR (B1 and B2) or a non-specific control (control), 24 h after transfection. Ordinary one-way ANOVA, ∗ p = 0.05, ∗∗ p = 0.005. (E) S YN GAP1 mRNA levels measured by qRT-PCR in SH-SY5Y cells transfected with two versions of booster V.2.0 (SB1 and SB2) targeting S YN GAP1 mRNA 3′ UTR or a non-specific control (control). SB2 showed a significant (∗) up to 4-fold increase in the mRNA level. Welch’s t test, ∗ p = 0.05.

Article Snippet: We tested our mRNA booster technology in HEK293 (ATCC CRL 1573), HEK293 SuperTopFlash (STF), and SH-SY5Y (ATCC CRL 2266) cell lines as well as iPSC-derived neuronal cells (see below).

Techniques: Quantitative RT-PCR, Transfection, Control

Journal: Molecular Therapy. Nucleic Acids

Article Title: Use of polyadenosine tail mimetics to enhance mRNA expression from genes associated with haploinsufficiency disorders

doi: 10.1016/j.omtn.2025.102453

Figure Lengend Snippet: Poly(A)-tail mimetics increase CTNNB1 expression in different cell types (A) Schematic of five distinct boosters along CTNNB1 3′ UTR, designed between nucleotide 376 and 1024. (B) The bar graph presents the result of quantified western blotting ( Figure S3 ) for CTNNB1 , showing the position and dose-dependent efficiency of the boosters targeting CTNNB1 compared to a non-specific booster control. To screen and select the most effective booster for CTNNB1 , HEK293-STF cells were transfected with different doses (10, 20, 30, 40, 50, and 100 nM) of five distinct CTNNB1 boosters V.1.0 (CB3, CB4, CB5, CB6, and CB7). Booster CB7 increases the protein level up to 2-fold compared to control at 40 nM booster or higher. (C) Representative western blotting and quantifications for three biological replicates showing the significant dose-dependent increase of CTNNB1 protein levels upon exposure to booster CB7 compared to control (for more blots and loading control, see Figure S3 ). Two-way ANOVA, ∗ p = 0.05, ∗∗∗ p = 0.0005. (D) qRT-PCR analysis confirms booster CB7 efficiency to increase CTNNB1 mRNA levels in a dose-dependent manner. Two-way ANOVA, ∗ p = 0.01. (E and F) mRNA levels of Wnt signaling pathway markers measured by qRT-PCR, illustrating the functional enhancement of CTNNB1 following the increase in CTNNB1 expression, in two different cell lines: HEK293-STF (E) and SH-SY5Y (F) cells. Welch’s t test, ∗ p < 0.05. (G and H) Protein levels of B-catenin and its downstream effector EN2 in β-catenin heterozygote, human iPSC-derived neurons, 48 h after transfection with LNP-packed boosters against CTNNB1 (CB7) or a non-specific control. Three different LNP formulations were tested (LNP1, LNP2, and LNP10; see Figure S2 ). (G) A representative western blot and (H) a quantitation of CTNNB1 and EN2 from western blots from two biological replicates.

Article Snippet: We tested our mRNA booster technology in HEK293 (ATCC CRL 1573), HEK293 SuperTopFlash (STF), and SH-SY5Y (ATCC CRL 2266) cell lines as well as iPSC-derived neuronal cells (see below).

Techniques: Expressing, Western Blot, Control, Transfection, Quantitative RT-PCR, Functional Assay, Derivative Assay, Quantitation Assay